» Articles » PMID: 38993600

Ablation of Primary and Recurrent Thyroid Cancer: Current and Future Perspectives

Overview
Specialty Radiology
Date 2024 Jul 12
PMID 38993600
Authors
Affiliations
Soon will be listed here.
Abstract

Thyroid cancer is the most common endocrine malignancy, and its incidence is increasing, driven in part by the advent of ultrasound, and subsequent increased detection of small, early thyroid cancers. Yet even for small tumors, thyroidectomy with lymph node dissection remains standard of care. Specific to well-differentiated thyroid cancer, surgery has come under scrutiny as a possible overtreatment, in light of stable and favorable survival rates even as guidelines have allowed fewer radical resections and lymph node dissections over time. Moreover, thyroid cancer unfortunately has a known recurrence rate regardless of therapy, and surgical re-intervention for local structural recurrence is eventually limited by scar. Radioactive iodine therapy, another accepted treatment, is minimally invasive but can only treat patients with iodine-avid tumors. For all of these reasons, image-guided thermal ablation has emerged as a valuable complementary tool as a thyroid-sparing, parathyroid-sparing, voice-sparing, repeatable, minimally invasive outpatient focal therapy for both primary and recurrent well-differentiated thyroid cancers. However, the data are still evolving, and this represents a new patient cohort for some interventional radiologists. Therefore, the goal of this review is to discuss the technique and evidence for ablation of patients with thyroid cancer.

References
1.
Chen J, Cao J, Qiu F, Huang P . The Efficacy and The Safety of Ultrasound-guided Ablation Therapy for Treating Papillary Thyroid Microcarcinoma. J Cancer. 2019; 10(21):5272-5282. PMC: 6775625. DOI: 10.7150/jca.36289. View

2.
Guenette J, Monchik J, Dupuy D . Image-guided ablation of postsurgical locoregional recurrence of biopsy-proven well-differentiated thyroid carcinoma. J Vasc Interv Radiol. 2013; 24(5):672-9. DOI: 10.1016/j.jvir.2013.02.001. View

3.
Miyauchi A, Kudo T, Ito Y, Oda H, Sasai H, Higashiyama T . Estimation of the lifetime probability of disease progression of papillary microcarcinoma of the thyroid during active surveillance. Surgery. 2017; 163(1):48-52. DOI: 10.1016/j.surg.2017.03.028. View

4.
Lewis B, Hay I, Charboneau J, McIver B, Reading C, Goellner J . Percutaneous ethanol injection for treatment of cervical lymph node metastases in patients with papillary thyroid carcinoma. AJR Am J Roentgenol. 2002; 178(3):699-704. DOI: 10.2214/ajr.178.3.1780699. View

5.
Shin J, Baek J, Ha E, Lee J . Radiofrequency ablation of thyroid nodules: basic principles and clinical application. Int J Endocrinol. 2012; 2012:919650. PMC: 3485526. DOI: 10.1155/2012/919650. View